VTCN1: A Potential Drug Target and Biomarker (G79679)
VTCN1: A Potential Drug Target and Biomarker
VTCN1, or Vimentin-1, is a protein that is expressed in various tissues throughout the body, including the skin, hair, and nails. It is a member of the vascular endothelial growth factor (VEGF) family, which includes multiple genes , such as VEGF, PLTGFR and FGF. VEGF family genes play an important role in the occurrence, growth and treatment of various tumors.
The expression level of VTCN1 is up-regulated in a variety of tumors, and the role of reduced expression levels in tumor treatment has also been extensively studied. Many studies have shown that the expression level of VTCN1 is positively correlated with tumor growth, invasion and metastasis capabilities. In addition, the expression level of VTCN1 is also related to the survival rate of tumor patients. Therefore, VTCN1 is considered a potential target for tumor treatment.
At the same time, VTCN1 also serves as a potential biomarker and has broad application prospects in tumor diagnosis, monitoring and treatment. For example, some studies have shown that the expression level of VTCN1 can be used to evaluate patient survival rate, as well as tumor invasiveness and metastasis. In addition, the expression level of VTCN1 can also be used as part of individualized treatment of tumors, because the expression level of VTCN1 may vary in different patients, resulting in differences in treatment response.
The pharmacological properties of VTCN1 also indicate its potential as a target for tumor treatment. It is known that anti-VEGF antibodies have been used to treat a variety of tumors, including skin cancer, basal cell carcinoma, lung cancer, and breast cancer. The mechanism of action of these anti-VEGF antibodies includes inhibiting the binding of VEGF to its receptors, thereby inhibiting tumor growth and metastasis. The anti-tumor effect of VTCN1 may be similar to its anti-VEGF effect. Therefore, VTCN1 may also become a target of anti-tumor drugs.
In order to further study the mechanism of action of VTCN1 and its potential as a target for tumor treatment, the researchers conducted a variety of experiments. For example, they studied the inhibitory effect of VTCN1 on the binding of VEGF receptors, the inhibitory effect of VTCN1 on the binding of fibrinogen, and the inhibitory effect of VTCN1 on the binding of vascular endothelial growth factor (VEGF). These experimental results indicate that VTCN1 has the ability to inhibit the binding of VEGF to its receptor, thereby inhibiting tumor growth and metastasis.
In addition, the researchers also studied the interaction of VTCN1 with tumor cells. They found that VTCN1 can bind to the vascular endothelial growth factor receptor (VEFR) on tumor cells, thereby promoting the sensitivity of tumor cells to growth factors. This interaction further demonstrates the important role of VTCN1 in tumor growth and treatment.
As a tumor target, VTCN1 has also been widely used in tumor treatment. For example, research on VTCN1 anti-tumor drugs has shown that VTCN1 anti-tumor drugs can inhibit tumor growth and metastasis, thereby improving patient survival rates. In addition, the detection of VTCN1 also has good prospects. For example, some studies have shown that by detecting the expression level of VTCN1, the survival rate of tumor patients can be predicted, thereby providing guidance for personalized treatment of tumor patients.
In summary, VTCN1, as a tumor target, has broad application prospects. By studying the mechanism of action of VTCN1, we can better understand the role of VTCN1 in tumor treatment and provide guidance for personalized treatment of tumor patients. Future research should further explore the application of VTCN1 in tumor treatment in order to provide better therapeutic effects and quality of life for tumor patients.
Protein Name: V-set Domain Containing T Cell Activation Inhibitor 1
Functions: Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation
The "VTCN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VTCN1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
VTI1A | VTI1B | VTN | VTRNA1-1 | VTRNA1-2 | VTRNA1-3 | VTRNA2-1 | VTRNA3-1P | VWA1 | VWA2 | VWA3A | VWA3B | VWA5A | VWA5B1 | VWA5B2 | VWA7 | VWA8 | VWC2 | VWC2L | VWCE | VWDE | VWF | VXN | WAC | WAC-AS1 | WAKMAR1 | WAKMAR2 | WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P | WASH6P | WASH7P | WASH8P | WASHC1 | WASHC2A | WASHC2C | WASHC3 | WASHC4 | WASHC5 | WASIR1 | WASL | WAVE1 complex | WBP1 | WBP11 | WBP11P1 | WBP1L | WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49
